Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Oct
14
Today In Oncology
Remote Exercise Program Reduces Cancer-Related Fatigue, Improves Quality of Life for Patients Undergoing Immunotherapy
ASCO Remembers Rachna Shroff Expert in Gastrointestinal Cancers
Implementing Massage and Acupuncture to Achieve Better Pain Management in Oncology Care: An Overview of the IMAGINE Project
Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutant NSCLC
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo